Ear­ly da­ta on Dai­ichi Sankyo’s Mer­ck-part­nered ADC; As­traZeneca’s Da­to-Dxd com­bo; more from Seagen: #ES­MO23 roundup

MADRID — Clin­i­cal re­searchers pre­sent­ed da­ta on hun­dreds of tri­als over the week­end at the Eu­ro­pean So­ci­ety for Med­ical On­col­o­gy Con­gress here in Spain.

Mer­ck and Dai­ichi set the tone with their three-ADC deal Thurs­day night, as many of the big stud­ies over the week­end in­volved an­ti­body-drug con­ju­gates.

Be­low is a re­cap of some of those stud­ies de­tailed at ES­MO, where about 30,000 re­searchers and bio­phar­ma in­dus­try pro­fes­sion­als have been run­ning around since Fri­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER